Movatterモバイル変換


[0]ホーム

URL:


Journal Logo

Email to Colleague

Colleague's E-mail is Invalid

Your Name:
Colleague's Email:
Separate multiple e-mails with a (;).
Message:

Your message has been successfully sent to your colleague.



Some error has occurred while processing your request. Please try after some time.

Export to

FAMILY PLANNING: Edited by Paul D. Blumenthal

Update on second trimester medical abortion

Lerma, Klaira; Shaw, Kate A.

Author Information

Division of Family Planning Services and Research, Department of Obstetrics and Gynecology, School of Medicine, Stanford University, Stanford, California, USA

Correspondence to Klaira Lerma, MPH, Stanford University School of Medicine, 300 Pasteur Drive, HG 332, Stanford, CA 94305, USA. Tel: +1 650 721 1562; e-mail:[email protected]

Current Opinion in Obstetrics and Gynecology29(6):p 413-418, December 2017. |DOI:10.1097/GCO.0000000000000409

Abstract

Purpose of review 

To review recent literature on second trimester abortion with medical methods.

Recent findings 

Across studies published in the recent past, it is apparent that women prefer shorter procedures and procedure times. Several randomized controlled trials have confirmed adding mifepristone to the second trimester medication abortion regimen results in shorter abortion intervals from first misoprostol administration to complete fetal expulsion. A study of simultaneous administration of mifepristone and misoprostol yielded shorter mean ‘total’ abortion times, presenting several logistical advantages. Recent studies on the continuous dosing of misoprostol have produced critical evidence to support continued dosing until expulsion. These studies had a more practical design compared with previous protocols that capped the number of misoprostol doses.

Summary 

Second trimester surgical abortion is well tolerated and increasingly expeditious. Further research is needed to refine second trimester medical abortion methods, specific to the mifepristone, misoprostol dosing interval. A 12-hour mifepristone to misoprostol interval may be the optimal interval balancing patient preferences and logistical considerations. Pragmatic dosing, including continuous dosing of misoprostol, could yield results that better inform clinical guidelines and reduce burden on patient, provider, and health facility.

Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.

You can read the full text of this article if you:

Log InAccess through Ovid

Source

Current Opinion in Obstetrics and Gynecology29(6):413-418, December 2017.
Email to Colleague

Colleague's E-mail is Invalid

Your Name:
Colleague's Email:
Separate multiple e-mails with a (;).
Message:

Your message has been successfully sent to your colleague.



Some error has occurred while processing your request. Please try after some time.


[8]ページ先頭

©2009-2025 Movatter.jp